Intravenous Vitamin C and Cancer: What Studies Show and What Is Claimed
What the National Cancer Institute, reviews and trials say about high-dose intravenous vitamin C in cancer, what is claimed by clinics, the safety risks, and why it is not a replacement for treatment.
Content last updated . This page has not been medically reviewed.
Start here
Intravenous (IV) vitamin C is not a substitute for cancer treatment. The National Cancer Institute (NCI) summary says the US Food and Drug Administration (FDA) has not approved high-dose vitamin C as a treatment for cancer. [1] If you have cancer, talk with your oncology team before using any IV or high-dose supplement, because some can interact with treatment or affect lab results. This page is information only. It does not tell anyone to start, change or stop a treatment.What is being claimed
Clinics and online sellers may describe IV vitamin C as a way to treat or "support" cancer, or to make chemotherapy work better or cause fewer side effects. We did not cite any seller's claims. The questions below are what published research and the NCI summary say. For other IV vitamin claims see IV vitamin therapy and ozone therapy claims and Claim check: IV vitamins boost energy and immunity.Why IV is different from tablets
When vitamin C is taken by mouth, blood levels are tightly controlled. NCI says the peak achievable concentration is less than 300 micromolar. With IV use that control is bypassed, giving levels up to 20 millimolar. [1] NCI also says IV doses over 500 mg produce much higher blood levels than the same oral dose. [1] So findings about oral vitamin C should not be applied to IV use, and the reverse.What studies show
| Question | What the source found | Strength of evidence |
|---|---|---|
| Two early oral trials | Two randomized placebo-controlled trials using oral vitamin C (10 g a day) without IV found no significant differences in symptoms, performance status or survival. [1] | No benefit found for oral use in those trials |
| Cells and animals | Laboratory studies reported that IV vitamin C decreased cell proliferation in several cancer cell lines. [1] | Preclinical |
| Animal studies and chemotherapy | Vitamin C has interfered with anticancer drug activity in some animal studies. [1] | Preclinical |
| Humans: tolerability and quality of life | IV vitamin C has been generally well tolerated in trials, and two studies reported improved quality of life and fewer cancer-related toxicities. NCI adds that the studies have limitations due to lack of rigor in trial design. [1] | Promising but limited |
| 2019 systematic review | 19 trials, only 4 randomized. The review says its results do not prove a clinically relevant benefit for overall survival, clinical status, quality of life or performance status, because study quality was low. [2] | Insufficient evidence |
| Prostate cancer, randomized phase II (2024) | 47 patients: adding IV vitamin C to docetaxel did not improve PSA response, toxicity or other clinical outcomes. [1] | No benefit found in that trial |
| Pancreatic cancer, randomized phase II (2024) | 34 patients: adding IV vitamin C to gemcitabine and nab-paclitaxel prolonged overall and progression-free survival, without detected loss of quality of life or added toxicity. [1] | Promising but limited (small) |
| 2025 meta-analysis of 8 studies | 2,722 adults: IV vitamin C was linked with longer median overall survival (ratio 1.83). The authors rated certainty moderate. Higher ratios came from cohort studies than from randomized trials. [3] | Mixed |
| 2026 review of benefits and risks | The role of high-dose IV vitamin C in oncology remains supportive and exploratory, with risks requiring caution. [4] | Insufficient evidence |
Randomized trials compare groups fairly. Cohort studies can be affected by who chose to receive treatment. A trial of a few dozen people cannot show whether a treatment extends life across a population. Biomarkers and quality-of-life scores differ from survival. The 2025 meta-analysis conclusion that IV vitamin C could be considered for standard care stands against the NCI's cautious wording and the 2024 prostate trial; this is a disagreement in the literature, not a settled answer.
Cure claims and replacing standard care: Proper evidence not found. We searched NCI's PDQ summary, PubMed systematic reviews and a 2026 review for any study showing IV vitamin C cures cancer or works instead of standard treatment and found none. See Choosing alternative medicine instead of cancer treatment.
Who should talk to their care team first
Anyone with cancer, anyone on chemotherapy or radiotherapy, people with kidney disease, G6PD deficiency, diabetes, iron overload, pregnancy, or those planning surgery. See Integrative care during cancer treatment, Antioxidant safety and marketing claims and How medication interactions work. The full vitamin profile is Vitamin C.Frequently asked questions
Does IV vitamin C cure cancer?
We found no study showing that. NCI says the FDA has not approved high-dose vitamin C as a cancer treatment. [1]
Is IV vitamin C the same as vitamin C tablets?
No. IV use bypasses the controls on blood levels that apply to oral use, reaching much higher concentrations. [1]
Is IV vitamin C safe during chemotherapy?
Trials report it was generally well tolerated, but interactions with some anticancer agents are a concern, mainly seen in preclinical studies. Ask your oncology team. [1]
What do the latest trials show?
Two 2024 phase II trials reported by NCI went in different directions: no improvement in prostate cancer, and longer survival in a small pancreatic cancer trial. [1]
Who should avoid high-dose IV vitamin C?
Case reports link it with hemolysis in G6PD deficiency and kidney injury in people with kidney disorders. [1]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
How to read the evidence labels
Labels used on this page: preclinical, promising but limited, insufficient evidence, mixed and Proper evidence not found.
Safety
- Kidneys: renal failure after ascorbic acid treatment has been reported in patients with existing kidney disorders. [1] A 2026 review lists oxalate nephropathy among the major risks. [4]
- G6PD deficiency: case reports indicate people with this condition should not receive high doses because of the risk of hemolysis. [1] A review of 14 case reports found most affected patients had G6PD deficiency and 57.1% received intravenous formulations. [5] Screening before IV use is suggested in the 2026 review. [4]
- Lab tests: high-dose IV vitamin C can cause falsely high readings on strip-based glucose meters. [1] Tell the care team about any IV vitamin C, particularly if you have diabetes. See High-dose vitamin C.
- Fluid overload was reported in one study of IV ascorbic acid, possibly related to how it was given. [1]
- Interactions with cancer drugs: NCI says high-dose vitamin C may interact adversely with some anticancer agents, mainly detected in preclinical studies. [1] NCI also notes that dietary supplements are not formally reviewed for manufacturing consistency every year, so ingredients may vary from lot to lot. [1]
- Quality of supplements and infusions: see Quality testing and certifications. Supplements used at home are not the same as IV vitamin C given in a clinical trial.
References
- National Cancer Institute (US). Intravenous Vitamin C (PDQ), health professional version. Summary updated 05/13/2025. Read 2026-10-23.
- Systematic review of vitamin C in the treatment of patients with cancer, Nutrients, 2019, PubMed 31035414. Read 2026-10-23.
- Systematic review and meta-analysis of intravenous vitamin C and survival in malignant neoplasm, International Journal for Vitamin and Nutrition Research, 2025, PubMed 40613397. Read 2026-10-23.
- Review of clinical benefits and risks of high-dose intravenous vitamin C, Journal of Medicine and Life, 2026, PubMed 41815850. Read 2026-10-23.
- Juneja D, Jain R, Nasa P. Vitamin C-induced hemolysis: meta-summary and review of literature. Indian Journal of Critical Care Medicine, 2022. Read 2026-10-23.